



oasmia

OASMIA PHARMACEUTICAL AB
COMPANY PRESENTATION
BIOTECH SHOWCASE, SAN FRANCISCO, USA
JANUARY 2020

Forward looking statement

IMPORTANT NOTICE:

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS:

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include, but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.


This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Corporate overview

We are an innovation-focused pharmaceutical company



HQ Uppsala, Sweden
Subsidiaries in USA,
Hong Kong and Moscow



NASDAQ Stockholm 2010
Frankfurt Stock Exchange 2011



60 employees



GMP certified production facility in
Sweden

Oasmia Technologies – Providing a universe of opportunities...



Animal health

- Lymphoma
- Mastocytoma
- Squamous Cell Carcinoma
- Mammary Carcinoma

Oncology

- Breast cancer
- Ovarian cancer
- Bladder cancer
- Prostate cancer
- Lung cancer
- Cervical cancer

Other

Therapeutic areas requiring i.v. administration of low-solubility compounds

...by solving the insoluble



A significant number of i.v. administered APIs have limited applications due to low water solubility



These drugs are made water soluble through solubility enhancers with more or less toxic substances which have the potential to complicate pharmacology and may require special precautions



Some substances require additional medication to blunt effects of solubilizers. These medications add their own pharmacologic action and/or undesired side effects

An estimated 40% of approved drugs and nearly 90% of the developmental pipeline drugs consist of poorly soluble molecules¹⁾

1) Kalepu S, Nekkanti V. Acta Pharmaceutica Sinica B; 2015: 442-453. <https://doi.org/10.1016/j.apsb.2015.07.003>

XR17™ – proprietary and patent protected solubility-enhancing technology platform

Active Pharmaceutical Ingredient (API)



Water in-soluble




XR17



Hydrophilic head
Hydrophobic chain



Micelle consisting of XR17 and API



Water soluble

Broad IP protection worldwide up to 2036

“Process”

Protects the manufacturing process for XR17

PCT application granted

3 patents granted
in US, ZA

Application pending in Eurasia, EPO, AU, CA, CN, HK, IN, ID, JP, MY, MX, NZ, KR, SG and UA

“Water-insoluble”

Protects poorly water-soluble APIs in combination with XR17

57 patents granted
across Eurasia, EPO, AU, CA, CN, JP, KR, MX, MY, NZ, UA, US, ZA

SPC applied for in the EU, pending
(5-year extension)

“Anticancer compositions”

Protects XR17 in combination with chemotherapeutic agents

6 patents granted
In US, FR, UK, DE, CN and HK

Key advantages of the XRI7™ platform

Proven clinical benefits

XRI7 platform



Novel platform based on vitamin A derivatives
In house research and development
Forms micelles, 10 – 60 nm size



Allows a high API-to-carrier ratio and thereby has the promise to reduce the risk of a biological effect of the carrier



Remarkable solubilizing properties
Enhances pharmacological profile and bioavailability of API



Alcohol free formulations
Free from substances of animal or human origin

Proven clinical benefits



Accepted safety profile in cancer indication



Shorter infusion time



No mandatory need for pre-medication



Free from Cremophor EL, Polysorbate-80, i.e. lower toxicity

Apealea™ – Using XR17™ technology

EMA approved for ovarian cancer



Approved in EU/EES for the treatment of 1st relapse ovarian cancer¹ and in and Russia for 1st line and 1st relapse ovarian cancer



Pre-medication not mandatory when treating with Apealea¹



One hour i.v. treatment time¹) vs 4-5 hours for competitor (cf. Taxol)




Enables increased dosing to 250 mg/m² with maintained tolerability¹ (cf. 175 mg/m² for Taxol)



Numerically less neuropathies¹ (cf. Taxol)

Apealea™ – new tool in the battle against ovarian cancer

Ovarian cancer incidence



In 2018, 295,000 women were diagnosed with ovarian cancer making it the 8th most common cancer type in women



Approximately 70% of women have a relapsing disease within three years after being diagnosed. 5 year survival is 46%



The most used therapeutic agents against ovarian cancer are platinum analogs in combination with paclitaxel

Apealea™ – a clear position in ovarian cancer



Standard of care

Carboplatin in combination with paclitaxel



Unmet need

A sub-set of patients cannot tolerate solvent-based paclitaxel (cf. Taxol)

Dependent on alternative treatments to achieve disease remission




The solution

Apealea – a solvent-free alternative to solvent-based paclitaxel


Indicated in combination with carboplatin for patients with first relapse of platinum-sensitive epithelial ovarian cancer

Patients dependent on alternative treatments¹⁾



1) Company estimations based on Sendo, T et al, Cancer Chemother Pharmacol (2005) 56: 91–96

Next steps for Apealea™



Oasmia Technologies – Providing a universe of opportunities...



Animal health

- Lymphoma
- Mastocytoma
- Squamous Cell Carcinoma
- Mammary Carcinoma

Oncology

- Breast cancer
- Ovarian cancer
- Bladder cancer
- Prostate cancer
- Lung cancer
- Cervical cancer


Other

Therapeutic areas requiring i.v. administration of low-solubility compounds

Our strong value proposition

Makes Oasmia an attractive partnering opportunity

1



Proprietary technology platform

XR17:
Broad Applicable technology

2



Proof of concept

Late-stage asset
Apealea (Paclical)
approved in EES
& Russia

3



Global market opportunity

Oncology market
estimated to reach
USD 176 billion
by 2025¹

4



Strong commercial partnerships

Global opportunities for commercialization

5



Dynamic Management Team

Highly experienced
Management Team
BoD, Scientific and
Business Advisory
Boards

1. Allied Market Research. Cancer Drugs Market 2019. www.alliedmarketresearch.com



oasmia

For more information visit www.oasmia.com
or send an email to business.development@oasmia.com